NCT03907397View on ClinicalTrials.gov

Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

August 5, 2019

Primary Completion Date

November 17, 2023

Study Completion Date

November 17, 2023

Conditions
Food AllergyPeanut Allergy
Interventions
BIOLOGICAL

Peanut Protein

up to 3 level teaspoons peanut butter or equivalent (approximately 3400 mg)

OTHER

Continued peanut avoidance

Standard of care avoidance of peanut

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Scott Sicherer

OTHER

NCT03907397 - Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy | Biotech Hunter | Biotech Hunter